Nivolumab is a type of immunotherapy drug that has been shown to impact cancer treatment positively. It is a programmed death receptor-1 (PD-1) blocking antibody, which helps to restore the body's immune system in fighting against cancer cells [1][2].

Nivolumab works by blocking the PD-1 pathway, which can be exploited by cancer cells to avoid detection and elimination by the immune system [1]. By inhibiting PD-1, nivolumab enables T-cells (a type of white blood cell) to identify and destroy cancer cells [2].

Clinical trials have demonstrated that nivolumab can be effective in treating several types of cancer, including melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, and head and neck squamous cell carcinoma [2].

According to Cancer Research UK, nivolumab can be used as a first-line treatment for advanced melanoma and non-small cell lung cancer, and it can also be used to treat relapsed or refractory classical Hodgkin lymphoma [3].

It is important to note that nivolumab can cause side effects, including fatigue, rash, diarrhea, and itching [2]. In rare cases, it can cause severe immune-related side effects, such as inflammation of the lungs, colon, or liver [2].

In summary, nivolumab is a type of immunotherapy drug that can restore the body's immune system in fighting against cancer cells. It has been shown to be effective in treating several types of cancer, although it can cause side effects.

Sources:
[1] <https://www.drugpatentwatch.com/p/biologics/ingredient/nivolumab>
[2] <https://www.cancer.gov/about-cancer/treatment/drugs/nivolumab>
[3] <https://www.cancerresearchuk.org/about-cancer/treatment/drugs/nivolumab>